Jefferies Downgrades Brightpoint (CELL) to Hold
Tweet Send to a FriendGet Alerts CELL Hot Sheet
Price: $8.98 --0%
Rating Summary:
1 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 43 | New: 13
Rating Summary:
1 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 21 | Down: 43 | New: 13
Trade CELL Now!
Jefferies downgraded Brightpoint (NASDAQ: CELL) from Buy to Hold with a price target of $11 (down from $12).
The firm said they see see risk/reward as more balanced especially in light of the stock's outperformance, an uncertain macro environment, and exposure to RIM (Nasdaq: RIMM), MMI (NYSE: MMI), Nokia (NYSE: NOK), and others likely share losers.
For more ratings news on Brightpoint click here and for the rating history of Brightpoint click here.
Shares of Brightpoint closed at $9.91 yesterday, with a 52 week range of $7.37-$13.22.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm said they see see risk/reward as more balanced especially in light of the stock's outperformance, an uncertain macro environment, and exposure to RIM (Nasdaq: RIMM), MMI (NYSE: MMI), Nokia (NYSE: NOK), and others likely share losers.
For more ratings news on Brightpoint click here and for the rating history of Brightpoint click here.
Shares of Brightpoint closed at $9.91 yesterday, with a 52 week range of $7.37-$13.22.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Wedbush Downgrades XenoPort (XNPT) to Neutral
- Jefferies Downgrades Bed Bath & Beyond (BBBY) to Hold
- Keefe, Bruyette & Woods Downgrades BlackRock (BLK) to Market Perform
Create E-mail Alert Related Categories
DowngradesRelated Entities
Jefferies & CoLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

